<DOC>
	<DOCNO>NCT02089828</DOCNO>
	<brief_summary>To compare efficacy cost-effectiveness purify CD34+ cell peripheral blood mononuclear cell treatment critical limb ischemia</brief_summary>
	<brief_title>Purified CD34+ Cells Versus Peripheral Blood Mononuclear Cells Treatment Critical Limb Ischemia</brief_title>
	<detailed_description />
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Arteritis</mesh_term>
	<mesh_term>Thromboangiitis Obliterans</mesh_term>
	<criteria>Rutherford scale 45 thromboangiitis obliterans , peripheral arterial disease , arteritis cause etiology , collagen disease surgical endovascular procedure consider unlikely successful longterm revascularization , fail 4 week critical limb ischemia present , nonhealing ulcer 4 week optimal care wound care physician nurse within 3 month acute myocardial infarction contraindication administration granulocyte colony stimulate factor ( GCSF )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>